Home » Viela Bio’s Uplizna Approved for Rare Autoimmune Disease
Viela Bio’s Uplizna Approved for Rare Autoimmune Disease
The FDA has approved Viela Bio’s Uplizna (inebilizumab-cdon) for intravenous treatment of neuromyelitis optica spectrum disorder in adults with a particular antibody.
The approval was based on the results of a clinical trial of 230 patients, in which the risk of relapse in treated patients was reduced by 77 percent compared to a placebo.
Uplizna is only the second treatment approved for the rare autoimmune disease, which affects the optic nerve and spinal cord. The FDA approved Alexion’s Soliris (eculizumab) in June 2019.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May